Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Immunovant, Inc.

NASDAQ: IMVT · Life Sciences · 8 alerts · CIK 1764013

Share price
$33.28Close, Nov 16
Market cap
$6.89B
Shares outstanding
206.95MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Immunovant, Inc. filings on SEC EDGAR ↗

7:21 AM ET 10-Q
Financial Results

Immunovant Q2 2026 Results: Net Loss of $97.2M, Loss Narrows

Immunovant reported a net loss of $97.2 million for the quarter ended September 30, 2026, compared to $126.5 million in the prior year period. The company maintained a strong liquidity position with $722.3 million in cash and cash equivalents, while research and development expenses remained the primary driver of operating costs at $85.0 million for the quarter.

Key figure
Net loss $97.2M
7:10 AM ET 8-K
Financial Results

Immunovant Financial Results

Immunovant reported financial results for its fiscal second quarter ended September 30, 2026, and announced positive topline data from a potentially registrational trial of IMVT-1402 in rheumatoid arthritis. The company ended the quarter with $722.3 million in cash and cash equivalents, which it expects will fund operations into 2028.

Term
Q2 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.